Trump's remarks came a day before the Fed was set to announce its next decision on interest rates.Politicsread more
In a tweet, Trump said that he and Xi "had a very good telephone conversation," and that "our respective teams will begin talks prior to our meeting."Politicsread more
Democratic Rep. Maxine Waters on Tuesday requested that Facebook pause its development of Libra, an upcoming cryptocurrency that the company plans to release in 2020.Technologyread more
Signs of companies moving out of Hong Kong have emerged, members of the business community told CNBC following massive protests in the city. But one analyst said Hong Kong's...China Politicsread more
Tensions between China and the U.S. are threatening to slow global trade further, threatening some Asian economies.Asia Economyread more
In its new "Future Skills" report, LinkedIn has identified what it calls the 10 "rising skills" of the future and the jobs associated with them.Get Aheadread more
Stocks in Asia rose in Wednesday morning trade following positive developments overnight on the U.S.-China trade front, while the offshore yuan jumped.Asia Marketsread more
U.S. President Donald Trump officially kicked off his reelection campaign Tuesday at a Florida rally where he exhorted thousands of rollicking supporters to keep advancing his...Politicsread more
Tesla loses vice president of HR and head of diversity, Felicia Mayo, one of a few black woman executives to break Silicon Valley's glass ceiling.Technologyread more
Union Pacific CEO Lance Fritz tells Jim Cramer that he is optimistic about trade relations with China, Mexico, Japan, and the EU.Mad Money with Jim Cramerread more
The S&P 500 is closing in on its all-time high, and is likely to sail past it, as long as the Fed promises lower interest rates and the trade war calms down.Market Insiderread more
Despite a drop in biotech stocks this week after political talk about price gouging, an analyst said Wednesday that the sector remains a good investment.
"Biotech and even specialty pharmaceuticals is still a stock picker's paradise," Corey Davis of Canaccord Genuity told CNBC's "Power Lunch. "
Price gouging has come to the forefront of news this week with commentary from Clinton as well as the controversy surrounding the drug Daraprim.
Davis attributes most of the downtick in the stocks to Clinton's tweet and subsequent rhetoric.
"It makes for great political rhetoric but at the end of the day, I don't think that any of these proposals are anything new or dramatic," he said about Clinton's proposed legislation. "I just don't think at the end of they day they're going pass and even if they do they're not going to have a material effect on the biopharm industry."
His top stock pick in the sector is Pacira Pharmaceuticals because, "it's been unduly beaten up and it's got a drug on the market and it's going to rebound nicely soon."
Disclosures: Neither Davis nor Canaccord Genuity own shares of Pacira Pharmaceuticals.